MKC-3946 combination indices (CI) with bortezomib or 17-AAG
. | Bortezomib, nM . | MKC-3946, μM . | CI . | 17-AAG, nM . | MKC-3946, μM . | CI . |
---|---|---|---|---|---|---|
RPMI 8226 | ||||||
3 | 5 | 1.04 | 125 | 5 | 1.06 | |
3 | 10 | 0.99 | 125 | 10 | 1.02 | |
4 | 5 | 0.91 | 250 | 5 | 0.89 | |
4 | 10 | 0.86 | 250 | 10 | 0.73 | |
INA6 | ||||||
2.5 | 5 | 1.14 | 31.3 | 5 | 1.04 | |
2.5 | 10 | 1.04 | 31.3 | 10 | 0.75 | |
3 | 5 | 1.06 | 62.5 | 5 | 0.76 | |
3 | 10 | 0.96 | 62.5 | 10 | 0.44 |
. | Bortezomib, nM . | MKC-3946, μM . | CI . | 17-AAG, nM . | MKC-3946, μM . | CI . |
---|---|---|---|---|---|---|
RPMI 8226 | ||||||
3 | 5 | 1.04 | 125 | 5 | 1.06 | |
3 | 10 | 0.99 | 125 | 10 | 1.02 | |
4 | 5 | 0.91 | 250 | 5 | 0.89 | |
4 | 10 | 0.86 | 250 | 10 | 0.73 | |
INA6 | ||||||
2.5 | 5 | 1.14 | 31.3 | 5 | 1.04 | |
2.5 | 10 | 1.04 | 31.3 | 10 | 0.75 | |
3 | 5 | 1.06 | 62.5 | 5 | 0.76 | |
3 | 10 | 0.96 | 62.5 | 10 | 0.44 |
RPMI 8226 and INA6 cells were treated with bortezomib or 17-AAG and/or MKC-3946. Cytotoxicity was assessed by [3H]-thymidine uptake. CI was calculated using CompuSyn software. CI < 0.9 indicates synergistic effects, and CI > 0.9 indicates additive effects.